Q3 2025 saw profitability and clinical progress, though revenue declined year-over-year due to high prior-year comparisons and currency headwinds. BD partnership rebounded, while wound management showed 8% YTD growth and is expected to deliver double-digit growth long-term.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.